Plandai Biotechnology, Inc. Announces New Product With Coyne Healthcare

Plandaí Biotechnology, Inc. (OTCQB:PLPL) announced a license agreement with Coyne Healthcare for a new product which will utilize the Company’s Pheroid^® entrapped Phytofare^® catechin complex — trade named “ph²™”– in a high-end consumer product for therapeutic and various other applications.
According to the company press release:

ph^2™ is the combination of the nano-entrapment system, Pheroid^® with the Company’s Phytofare^® catechin complex. Pheroid^® encapsulates, or entraps, the Phytofare^® in a long-chain fatty-acid which both improves absorption and protects the Phytofare^® against metabolization during the digestive process. Pheroid^® is actively used worldwide for industrial and agricultural purposes and has been extensively tested in humans and animals where it has shown an ability to significantly increase the level of absorption of the entrapped particles into the bloodstream. The new Coyne Healthcare product represents the first application of Phytofare® and Pheroid® (branded “ph²™”) in a commercial product intended for human use.

Callum Cottrell-Duffield, Vice President of Plandaí, commented:

Coyne Healthcare’s vision for creating a high-end wellness product is represented by their insistence on using the best ingredients available and then packaging and marketing them in an exclusive format. Together we believe that customers are tired of buying products whose active ingredients simply fail to deliver the desired results. ph^2™provides customers with a therapeutic level of all 8 catechins and then protects these valuable, thermogenic-producing molecules until they reach the blood stream. We’re excited to be working together and anticipate great things for their product.

Click here to view the full press release.